MX2008013039A - Metodo para aliviar la queratoconjuntivitis sicca. - Google Patents

Metodo para aliviar la queratoconjuntivitis sicca.

Info

Publication number
MX2008013039A
MX2008013039A MX2008013039A MX2008013039A MX2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A
Authority
MX
Mexico
Prior art keywords
alleviating
keratoconjunctivitis sicca
tear production
compound
topical
Prior art date
Application number
MX2008013039A
Other languages
English (en)
Inventor
Joel Bernstein
Original Assignee
Winston Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winston Lab Inc filed Critical Winston Lab Inc
Publication of MX2008013039A publication Critical patent/MX2008013039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La presente invención describe un método mejorado para aumentar la producción de lágrimas mediante la administración intranasalmente de una cantidad terapéuticamente efectiva de un compuesto capsaicinoide a pacientes con una producción deficientes de lágrimas. La incorporación opcional en la formulación intranasal de un corticosteroide tópico o compuesto anestésico tópico se usa para reducir la picazón y quemazón nasal transiente que a menudo pueden acompañar la administración intranasal de los capsaicinoides.
MX2008013039A 2007-10-05 2007-10-08 Metodo para aliviar la queratoconjuntivitis sicca. MX2008013039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/868,286 US20090093446A1 (en) 2007-10-05 2007-10-05 Method for alleviating keratoconjunctivitis sicca
PCT/US2007/080707 WO2009045224A1 (en) 2007-10-05 2007-10-08 Method for alleviating keratoconjunctivitis sicca

Publications (1)

Publication Number Publication Date
MX2008013039A true MX2008013039A (es) 2009-06-05

Family

ID=40523784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013039A MX2008013039A (es) 2007-10-05 2007-10-08 Metodo para aliviar la queratoconjuntivitis sicca.

Country Status (13)

Country Link
US (1) US20090093446A1 (es)
EP (1) EP2094256A4 (es)
JP (1) JP2009545634A (es)
KR (1) KR20090080017A (es)
CN (1) CN101616663A (es)
AR (1) AR068669A1 (es)
AU (1) AU2007349197A1 (es)
BR (1) BRPI0710595A2 (es)
CA (1) CA2644733A1 (es)
IL (1) IL198657A0 (es)
MX (1) MX2008013039A (es)
NZ (1) NZ571467A (es)
WO (1) WO2009045224A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166925B2 (en) 2018-08-23 2021-11-09 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019203A2 (en) * 2010-08-03 2012-02-09 Dynova Laboratories, Inc. Therapeutic agent for intranasal administration and method of making and using same
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
JP2013542838A (ja) 2010-11-16 2013-11-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ドライアイを治療するためのシステムおよび方法
CA2840932C (en) * 2011-07-07 2020-01-21 Eva MILLQVIST Cough reducing product
AU2013305569A1 (en) * 2012-08-24 2015-02-19 Vr1, Inc. Composition for the treatment of migraine headaches
NZ704579A (en) 2013-04-19 2018-10-26 Oculeve Inc Nasal stimulation devices and methods
KR102511955B1 (ko) 2014-10-20 2023-03-22 오이스터 포인트 파마 인코포레이티드 안과 질환의 치료 방법
AU2015335776B2 (en) * 2014-10-22 2020-09-03 Oculeve, Inc. Stimulation devices and methods for treating dry eye
CN114533737A (zh) 2016-04-07 2022-05-27 奥伊斯特普安生物制药公司 治疗眼部病状的方法
WO2017192572A1 (en) 2016-05-02 2017-11-09 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
TW202019424A (zh) * 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
KR20210021017A (ko) * 2018-08-23 2021-02-24 엘로락, 인크. 건성각결막염을 경감시키기 위한 방법 및 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134166A (en) * 1988-12-02 1992-07-28 Genderm Corporation Method for treating nasal disorders and headaches
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
US5063060A (en) * 1989-12-19 1991-11-05 Cisco Limited Partnership Compositions and method for treating painful, inflammatory or allergic disorders
EP0646372B1 (de) * 1993-09-30 1999-03-31 Medichemie Ag Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie
CH690023A5 (de) * 1996-02-02 2000-03-31 Medichemie Ag Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
IL137128A0 (en) * 1998-01-30 2001-07-24 R Tech Ueno Ltd Ophthalmic compositions containing tetrahydroquinazoline derivatives
JP4653516B2 (ja) * 2004-02-27 2011-03-16 扶桑薬品工業株式会社 涙液分泌促進ペプチドおよびその組成物
DE102004063363A1 (de) * 2004-06-28 2006-01-19 Weber, Erhard, Dr. Capsaicin-haltige Arzneien zur Behandlung von Bronchial-Infekten und Allergien
MX2007006253A (es) * 2004-11-24 2007-10-18 Anesiva Inc Formulacion de gel de capsaicinoide y usos para esta.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166925B2 (en) 2018-08-23 2021-11-09 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca
US11478439B2 (en) 2018-08-23 2022-10-25 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca

Also Published As

Publication number Publication date
KR20090080017A (ko) 2009-07-23
CA2644733A1 (en) 2009-04-05
WO2009045224A1 (en) 2009-04-09
CN101616663A (zh) 2009-12-30
BRPI0710595A2 (pt) 2011-08-16
EP2094256A4 (en) 2009-11-11
NZ571467A (en) 2009-03-31
AU2007349197A1 (en) 2009-04-23
IL198657A0 (en) 2010-02-17
EP2094256A1 (en) 2009-09-02
JP2009545634A (ja) 2009-12-24
AR068669A1 (es) 2009-11-25
US20090093446A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
MX2008013039A (es) Metodo para aliviar la queratoconjuntivitis sicca.
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MY139577A (en) Anti-inflammatory androstane derivative
AU2024202233A1 (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
MX2010001236A (es) Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
MX2010006284A (es) Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.
NZ599136A (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
WO2012027693A3 (en) Pharmaceutical compositions comprising poh derivatives
WO2011141929A3 (en) Aqueous pharmaceutical compositions of fluticasone and olopatadine
WO2006047476A3 (en) Therapeutic and delivery methods of prostaglandin ep4 agonists
MX2012013212A (es) Forma farmaceutica oral resistente al alcohol.
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
TW200603787A (en) Topical preparations containing ambroxol
WO2007134241A3 (en) Nasal delivery of therapeutic agents using tight junction agonists
MY192033A (en) Method of dosing and use of soft anticholinergic esters
WO2012007159A3 (en) Novel gastro-retentive dosage forms
HK1176318A1 (en) Injection device
RU2011101151A (ru) Интраназальные композиции, содержащие деконгестант и кортикостероид
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2011011126A (es) Composiciones y metodos para tratar quemaduras.
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
WO2009015485A8 (en) Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
NZ597488A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease

Legal Events

Date Code Title Description
FA Abandonment or withdrawal